Efetividade e segurança do uso da Cannabis sativa no tratamento dos sintomas não-motores na Doença de Parkinson: Uma revisão de escopo
DOI:
https://doi.org/10.33448/rsd-v13i12.47643Palavras-chave:
Cannabis sativa; Doença de Parkinson; Sintomas Não-Motores.Resumo
Objetivo: Mapear e analisar as evidências disponíveis na literatura existente acerca da efetividade e segurança do uso da Cannabis sativa no tratamento dos Sintomas Não-Motores (SNM) da Doença de Parkinson (DP). Metodologia: Trata-se de uma revisão de escopo, com busca realizada nas bases de dados BVS Direct, EBSCO, Embase, PubMed e Scopus, sem limite temporal ou de idioma. Este processo foi norteado pela pergunta de pesquisa “Quais são as evidências da efetividade e segurança do uso terapêutico de Cannabis sativa no tratamento dos sintomas não-motores em pacientes com Doença de Parkinson?”. Resultados: Dos 2193 artigos encontrados, 90 estudos foram considerados elegíveis. Os estudos indicaram que a Cannabis sativa possui potencial para tratar diversos SNM, com melhora significativa da dor e distúrbios do sono, bem como melhora em manifestações neuropsiquiátricas e da qualidade de vida. As taxas de efeitos colaterais tendem a ser baixas e geralmente são classificados como leves e bem tolerados. No entanto, os resultados variam dependendo da dose utilizada, forma de administração do produto e composto canabinoide utilizado, sendo necessário mais estudos para avaliar a sua efetividade e segurança. Conclusão: O uso da Cannabis sativa pode melhorar os SNM, com potencial para impactar positivamente a qualidade de vida dos portadores de DP. Entretanto, mais estudos são necessários para garantir a efetividade e segurança dessa terapia complementar.
Referências
Agar, E. (2015). The role of cannabinoids and leptin in neurological diseases. Acta Neurologica Scandinavica, 132(5), 371-380. https://doi.org/10.1111/ane.12411
Almeida, C. M. O., Brito, M. M. C., Bosaipo, N. B., Pimentel, A. V., Tumas, V., Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., & Eckeli, A. L. (2021). Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder. Movement Disorders. https://doi.org/10.1002/mds.28577
Almeida, C. M. O., Brito, M. M. C., Bosaipo, N. B., Pimentel, A. V., Sobreira-Neto, M. A., Tumas, V., Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., & Eckeli, A. L. (2022). The effect of cannabidiol for restless legs syndrome/Willis-Ekbom disease in Parkinson’s disease patients with REM sleep behavior disorder: A post hoc exploratory analysis of phase 2/3 clinical trial. Cannabis and Cannabinoid Research, X(X), 1-5. https://doi.org/10.1089/can.2021.0158
Almeida, C. M. O., Pachito, D. V., Sobreira-Neto, M. A., Tumas, V., & Eckeli, A. L. (2018). Pharmacological treatment for REM sleep behavior disorder in Parkinson disease and related conditions: A scoping review. Journal of the Neurological Sciences, 393, 63-68. https://doi.org/10.1016/j.jns.2018.08.008
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020). Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol. Pharmacological Research, 157, 104822. https://doi.org/10.1016/j.phrs.2020.104822
Aromataris, E., & Munn, Z. (Eds.). (2020). JBI manual for evidence synthesis. JBI. Disponível em: https://synthesismanual.jbi.global. https://doi.org/10.46658/JBIMES-24-01
Arksey, H., & O’Malley, L. (2005). Scoping studies: towards a methodological framework. International Journal of Social Research Methodology, 8(1), 19–32. https://doi.org/10.1080/1364557032000119616
Babayeva, M., Assefa, H., Basu, P., Chumki, S., & Loewy, Z. (2016). Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.
Parkinson's Disease, 2016, Article ID 1279042. https://doi.org/10.1155/2016/1279042
Bahji, A., Breward, N., Duff, W., Absher, N., Patten, S. B., Alcorn, J., & Mousseau, D. D. (2022). Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: A mixed studies systematic review. Journal of Cannabis Research, 4(11). https://doi.org/10.1186/s42238- 022-00119-y
Balash, Y., Schleider, L. B. L., Korczyn, A. D., Shabtai, H., Knaani, J., Rosenberg, A., Baruch, Y., Djaldetti, R., Giladi, N., & Gurevich, T. (2017). Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience. Clinical Neuropharmacology, 40(2), 268-272. https://doi.org/10.1097/WNF.0000000000000246
Bergamaschi, M. M., Queiroz, R. H. C., Zuardi, A. W., & Crippa, J. A. S. (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Current Drug Safety, 6(4), 237-249. https://doi.org/10.2174/157488611798280924
Bougea, A., Koros, C., Simitsi, A.-M., Chrysovitsanou, C., Leonardos, A., & Stefanis, L. (2020). Medical cannabis as an alternative therapeutics for Parkinsons’ disease: Systematic review. Complementary Therapies in Clinical Practice, 39, 101154. https://doi.org/10.1016/j.ctcp.2020.101154
Buhmann, C., Kassubek, J., & Jost, W. H. (2020). Management of pain in Parkinson’s disease. Journal of Parkinson’s Disease, 10(S1), S37-S48. https://doi.org/10.3233/JPD-202069
Bhunia, S., Kolishetti, N., Arias, A. Y., Vashist, A., & Nair, M. (2022). Cannabidiol for neurodegenerative disorders: A comprehensive review. Frontiers in Pharmacology, 13, 989717. https://doi.org/10.3389/fphar.2022.989717
Brucki, S. M. D., Frota, N. A., Schestatsky, P., Souza, A. H., Carvalho, V. N., Manreza, M. L. G., Mendes, M. F., Comini-Frota, E., Vasconcelos, C., Tumas, V., Ferraz, H. B., Barbosa, E., & Jurno, M. E. (2015). Cannabinoids in neurology – Brazilian Academy of Neurology. Arquivos de Neuro-Psiquiatria, 73(4), 371-374. https://doi.org/10.1590/0004-282X20150041
Cabreira, V., & Massano, J. (2019). Doença de Parkinson; Revisão clínica e atualização. Acta Médica Portuguesa, 32(10), 661-670. https://doi.org/10.20344/amp.11978
Camargo Filho, M. F. de A., Romanini, A. P., Pyrich, B. C., Pedri, E., Fontoura, G. C., Zorrer, L. A., Gonçalves, V. D. M. de A., Gianini, V. C. M., & Müller,
J. C. (2019). Canabinoides como uma nova opção terapêutica nas doenças de Parkinson e de Alzheimer: uma revisão de literatura. Revista Brasileira de Neurologia, 55(2), 17-32. http://fi-admin.bvsalud.org/document/view/nsxb2
Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E. C., & Crippa, J. A. S. (2014a). Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial. Journal of Psychopharmacology, 28(11), 1088-1092. https://doi.org/10.1177/0269881114550355
Chagas, M. H. N., Eckeli, A. L., Zuardi, A. W., Pena-Pereira, M. A., Sobreira-Neto, M. A., Sobreira, E. T., Camilo, M. R., Bergamaschi, M. M., Schenck, C. H., Hallak, J. E. C., Tumas, V., & Crippa, J. A. S. (2014b). Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: A case series. Journal of Clinical Pharmacy and Therapeutics, 39(5), 564-566. https://doi.org/10.1111/jcpt.12179
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006). Non-motor symptoms of parkinson’s disease: Diagnosis and management. The Lancet Neurology, 5(3), 235–245. https://doi.org/10.1016/s1474-4422(06)70373-8
Costa, A. C., Joaquim, H. P. G., Pedrazzi, J. F. C., Pain, A. d. O., Duque, G., & Aprahamian, I. (2022). Cannabinoids in late life Parkinson’s disease and dementia: Biological pathways and clinical challenges. Brain Sciences, 12(12), 1596. https://doi.org/10.3390/brainsci12121596
Cravanas, B. Jr., & Frei, K. (2020). The effects of Cannabis on hallucinations in Parkinson’s disease patients. Journal of the Neurological Sciences, 419, 117206. https://doi.org/10.1016/j.jns.2020.117206
Crippa, J. A. S., Hallak, J. E. C., Zuardi, A. W., Guimarães, F. S., Tumas, V., & dos Santos, R. G. (2019). Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms? European Archives of Psychiatry and Clinical Neuroscience, 269, 53-56. https://doi.org/10.1007/s00406-019-00982-6
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018). Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Frontiers in Immunology, 9, Article 2009. https://doi.org/10.3389/fimmu.2018.02009
Dash, R., Ali, M. C., Jahan, I., Munni, Y. A., Mitra, S., Hannan, M. A., Timalsina, B., Oktaviani, D. F., Choi, H. J., & Moon, I. S. (2020). Emerging potential of cannabidiol in reversing proteinopathies. Ageing Research Reviews. https://doi.org/10.1016/j.arr.2020.101209
del Toro Pérez, C., Amaya Pascasio, L., Arjona Padillo, A., Olivares Romero, J., Mejías Olmedo, M. V., Fernández Pérez, J., Payán Ortiz, M., & Martínez- Sánchez, P. (2021). Neurosonological findings related to non-motor features of Parkinson’s disease: A systematic review. Brain Sciences, 11(6), 776. https://doi.org/10.3390/brainsci11060776
Deuel, L. M., & Seeberger, L. C. (2020). Complementary therapies in Parkinson disease: a review of acupuncture, Tai Chi, Qi Gong, yoga, and cannabis.
Neurotherapeutics, 17(3), 1434-1455. https://doi.org/10.1007/s13311-020-00900-y
Díaz Rodríguez, L. S., López Mirón, A. E., & Romero Olmedo, A. A. (2023). Uso de cannabidiol para el control de síntomas refractarios en síndromes convulsivos y enfermedades neurodegenerativas. Alerta, 6(1), 78-85. https://doi.org/10.5377/alerta.v6i1.15563
Durán-Ferreras, E., & Chacón, J. R. (2009). Tratamiento de la psicosis parkinsoniana. Revista de Neurología, 48(12), 645-653. https://doi.org/10.33588/rn.4812.2008573
Ellmerer, P., Peball, M., Carbone, F., Ritter, M., Heim, B., Marini, K., Valent, D., Krismer, F., Poewe, W., Djamshidian, A., & Seppi, K. (2022). Eye tracking in patients with Parkinson’s disease treated with nabilone–Results of a phase II, placebo-controlled, double-blind, parallel-group pilot study. Brain Sciences, 12(5), 661. https://doi.org/10.3390/brainsci12050661
Erga, A. H., Maple-Grødem, J., & Alves, G. (2022). Cannabis use in Parkinson’s disease—A nationwide online survey study. Acta Neurologica Scandinavica, 145(6), 692-697. https://doi.org/10.1111/ane.13602
Faria, S. M. de, Fabrício, D. de M., Tumas, V., Castro, P. C., Ponti, M. A., Hallak, J. E. C., Zuardi, A. W., Crippa, J. A. S., & Chagas, M. H. N. (2020). Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. Journal of Psychopharmacology, 34(1), 1-8. https://doi.org/10.1177/0269881119895536
Feeney, M. P., Bega, D., Kluger, B. M., Stoessl, A. J., Evers, C. M., De Leon, R., & Beck, J. C. (2021). Weeding through the haze: A survey on cannabis use among people living with Parkinson’s disease in the US. npj Parkinson's Disease, 7(21). https://doi.org/10.1038/s41531-021-00165-y
Fernandes, I., & Andrade Filho, A. S. (2018). Estudo clínico-epidemiológico de pacientes com Doença de Parkinson em Salvador-Bahia. Revista Brasileira de Neurologia e Psiquiatria, 22(1), 45-59. Disponível em: https://www.revneuropsiq.com.br/rbnp/article/view/244/141
Fernandes, M., Pierantozzi, M., Stefani, A., Cattaneo, C., Bonizzoni, E. A., Cerroni, R., Mercuri, N. B., & Liguori, C. (2021). Frequency of non-motor symptoms in Parkinson's patients with motor fluctuations. Frontiers in Neurology, 12, 678373. https://doi.org/10.3389/fneur.2021.678373
Ferreira, C., Almeida, C., Tenreiro, S., & Quintas, A. (2020). Neuroprotection or neurotoxicity of illicit drugs on Parkinson’s disease. Life, 10(6), 86. https://doi.org/10.3390/life10060086
Ferreira, G., Gonçalves, C. C. A., Filho, S. C. da S., & Soares, D. A. (2022). Efeitos positivos do uso de canabidiol em pacientes com Doença de Parkinson / Positive effects of cannabidiol use in patients with Parkinson’s disease. Brazilian Journal of Development, 8(2), 9051-9059. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BRJD/article/view/43667.
Ferreira-Junior, N. C., Campos, A. C., Guimarães, F. S., Del-Bel, E., Zimmermann, P. M. da R., Brum Junior, L., Hallak, J. E., Crippa, J. A., & Zuardi, A. W. (2020). Biological bases for a possible effect of cannabidiol in Parkinson’s disease. Brazilian Journal of Psychiatry, 42(2), 218-224. https://doi.org/10.1590/1516-4446-2019-0460
Fiani, B., Sarhadi, K. J., Soula, M., Zafar, A., & Quadri, S. A. (2020). Current application of cannabidiol (CBD) in the management and treatment of neurological disorders. Neurological Sciences. https://doi.org/10.1007/s10072-020-04514-2
Figura, M., Koziorowski, D., & Sławek, J. (2022). Cannabis in Parkinson’s Disease — the patient’s perspective versus clinical trials: a systematic literature review. Neurologia i Neurochirurgia Polska, 56(1), 21-26. https://doi.org/10.5603/PJNNS.a2022.0004
Finseth, T. A., Hedeman, J. L., Brown, R. P. II, Johnson, K. I., Binder, M. S., & Kluger, B. M. (2015). Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson’s disease patients in Colorado. Evidence-Based Complementary and Alternative Medicine, 2015, Article ID 874849. https://doi.org/10.1155/2015/874849
Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018). Medical use of cannabinoids. Drugs, 78(16), 1665-1703. https://doi.org/10.1007/s40265-018-0996-1
Ghaffari, B. D., & Kluger, B. (2014). Mechanisms for alternative treatments in Parkinson’s disease: Acupuncture, Tai Chi, and other treatments. Current Neurology and Neuroscience Reports, 14(10), 451. https://doi.org/10.1007/s11910-014-0451-y
Hawes, E. M., Lee, C. R., Brackney, D. E., Ensley, T. G., Kidd, J., & Page, C. (2020). Cannabidiol products: Review of the regulatory and clinical considerations.
The Journal for Nurse Practitioners. https://doi.org/10.1016/j.nurpra.2020.07.022
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012). Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics, 133(1), 79-97. https://doi.org/10.1016/j.pharmthera.2011.09.002
Holden, S. K., Domen, C. H., Sillau, S., Liu, Y., & Leehey, M. A. (2022). Higher risk, higher reward? Self-reported effects of real-world cannabis use in Parkinson’s disease. Movement Disorders Clinical Practice, 9(3), 340-350. https://doi.org/10.1002/mdc3.13414
Honório, K. M., Arroio, A., & Silva, A. B. F. (2006). Aspectos terapêuticos de compostos da planta Cannabis sativa. Química Nova, 29(2), 318-325. Disponível em: https://www.scielo.br/j/qn/a/LmPbLrC3DY6Z68BK6cMHPbf/?format=pdf&lang=pt
Jost, W. H., & Buhmann, C. (2019). The challenge of pain in the pharmacological management of Parkinson’s disease. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2019.1639672
Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. The Lancet, 386(9996), 896–912. https://doi.org/10.1016/S0140-6736(14)61393-3
Kanjanarangsichai, A., Mitarnun, W., Mitarnun, W., Pangwong, W., Laoharattanahirun, N., Kajornrith, W., Junlaor, P., Nonghan, P., Witthayapirote, W., & Sangkarom, G. (2022). Cannabidiol-enriched cannabis extraction product in Parkinson’s disease: A randomized, double-blind, and placebo-controlled trial in Buriram Hospital. Journal of Neurosciences in Rural Practice, 13(4), 663-668. https://doi.org/10.25259/JNRP-2022-6-19
Kim, H., Zhang, S., & Sin, M.-K. (2022). Cannabidiol (CBD) consideration in Parkinson disease. The Journal for Nurse Practitioners, 18(6), 611-613. https://doi.org/10.1016/j.nurpra.2022.04.006
Kolongowski, B., & Tjiattas-Saleski, L. (2021). Cannabidiol: Background and Literature Review of Potential Treatments. Osteopathic Family Physician, 13(2), 16-23. https://doi.org/10.33181/13022
Lacroix, C., Alleman-Brimault, I., Zalta, A., Rouby, F., Cassé-Perrot, C., Jouve, E., Attolini, L., Guilhaumou, R., Micallef, J., & Blin, O. (2022). What do we know about medical cannabis in neurological disorders and what are the next steps? Frontiers in Pharmacology, 13, 883987. https://doi.org/10.3389/fphar.2022.883987
Leehey, M. A., Liu, Y., Hart, F., Epstein, C., Cook, M., Sillau, S., Klawitter, J., Newman, H., Sempio, C., Forman, L., Seeberger, L., Klepitskaya, O., Baud, Z., & Bainbridge, J. (2020). Safety and tolerability of cannabidiol in Parkinson disease: An open label, dose-escalation study. Cannabis and Cannabinoid Research, X(X), XX-XX. https://doi.org/10.1089/can.2019.0068
Legare, C. A., Raup-Konsavage, W. M., & Vrana, K. E. (2022). Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals.
Pharmacology, 107(3-4), 131-149. https://doi.org/10.1159/000521683
Lotan, I., Treves, T. A., Roditi, Y., & Djaldetti, R. (2014). Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clinical Neuropharmacology, 37(2), 41-44. https://doi.org/10.1097/WNF.0000000000000016
Mainka, T., Stork, J., Hidding, U., & Buhmann, C. (2018). Cannabis in Parkinson’s Disease: Hype or help? Fortschritte der Neurologie-Psychiatrie, 86(12), 773-780. https://doi.org/10.1055/s-0043-120668
Mechoulam, R. (2016). Cannabis – the Israeli perspective. Journal of Basic and Clinical Physiology and Pharmacology, 27(3), 181-187. https://doi.org/10.1515/jbcpp-2015-0091
Mendonça, I. P., Duarte-Silva, E., Chaves-Filho, A. J. M., Andrade da Costa, B. L. da S., & Peixoto, C. A. (2020). Neurobiological findings underlying depressive behavior in Parkinson’s disease: A review. International Immunopharmacology, 83, 106434. https://doi.org/10.1016/j.intimp.2020.106434
Micheli, F. E., Groppo, J., Contartese, M. L., Baccaglio, P. G., Borisonik, L. N., Lakos, C., Barros, J. P., Maiola, R. P., Arakaki, T., Garretto, N. S., Giannaula,
R. J., & Pecci, M. C. (2020). Cannabis in patients with Parkinson's disease in Argentina: A cross-sectional study. Parkinsonism and Related Disorders, 78, 66- 67. https://doi.org/10.1016/j.parkreldis.2020.06.033
Millar, S. A., Stone, N. L., Bellman, Z. D., Yates, A. S., England, T. J., & O'Sullivan, S. E. (2019). A systematic review of cannabidiol dosing in clinical populations. British Journal of Clinical Pharmacology, 85(8), 1888-1900. https://doi.org/10.1111/bcp.14038
Morris, M., Chye, R., Liu, Z., Agar, M., & Razmovski-Naumovski, V. (2023). A retrospective medical record review of adults with non-cancer diagnoses prescribed medicinal cannabis. Journal of Clinical Medicine, 12(4), 1483. https://doi.org/10.3390/jcm12041483
Mylius, V., Möller, J. C., Bohlhalter, S., Ciampi de Andrade, D., & Perez Lloret, S. (2021). Diagnosis and management of pain in Parkinson’s disease: A new approach. Drugs & Aging. https://doi.org/10.1007/s40266-021-00867-1
Noel, C. (2017). Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders. Mental Health Clinician, 7(1), 29-38. https://doi.org/10.9740/mhc.2017.01.029
Oikonomou, P., & Jost, W. H. (2022). Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review. Journal of Neural Transmission, 129(10), 1247-1256. https://doi.org/10.1007/s00702-022-02529-x
Ortiz, Y. T., McMahon, L. R., & Wilkerson, J. L. (2022). Medicinal cannabis and central nervous system disorders. Frontiers in Pharmacology, 13, 881810. https://doi.org/10.3389/fphar.2022.881810
O’Sullivan, S. E., Stevenson, C. W., & Laviolette, S. R. (2021). Could cannabidiol be a treatment for coronavirus disease-19-related anxiety disorders? Cannabis and Cannabinoid Research, 6(1), 7-16. https://doi.org/10.1089/can.2020.0102
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan - a web and mobile app for systematic reviews. Systematic Reviews, 5(1), 210. https://doi.org/10.1186/s13643-016-0384-4
Owusu, K. A., Saliba, L., Ammar, A. A., Ammar, M. A., & Mucksavage, J. (2020). Application of cannabinoids in neurosciences: Considerations and implications. Critical Care Nursing Quarterly, 43(2), 216-231. https://doi.org/10.1097/CNQ.0000000000000303
Paes-Colli, Y., Aguiar, A. F. L., Isaac, A. R., Ferreira, B. K., Campos, R. M. P., Trindade, P. M. P., de Melo Reis, R. A., & Sampaio, L. S. (2022). Phytocannabinoids and cannabis-based products as alternative pharmacotherapy in neurodegenerative diseases: From hypothesis to clinical practice. Frontiers in Cellular Neuroscience, 16, 917164. https://doi.org/10.3389/fncel.2022.917164
Patel, R. S., Kamil, S., Shah, M. R., Bhimanadham, N. N., & Imran, S. (2019). Pros and Cons of Marijuana in Treatment of Parkinson’s Disease. Cureus, 11(6), e4813. https://doi.org/10.7759/cureus.4813
Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020). Cannabidiol as a therapeutic target: Evidence of its neuroprotective and neuromodulatory function in Parkinson’s disease. Frontiers in Pharmacology, 11, 595635. https://doi.org/10.3389/fphar.2020.595635
Pauli, C. S., Conroy, M., Vanden Heuvel, B. D., & Park, S.-H. (2020). Cannabidiol drugs clinical trial outcomes and adverse effects. Frontiers in Pharmacology, 11, 63. https://doi.org/10.3389/fphar.2020.00063
Peball, M., Seppi, K., Krismer, F., Knaus, H.-G., Spielberger, S., Heim, B., Ellmerer, P., Werkmann, M., Poewe, W., & Djamshidian, A. (2022). Effects of nabilone on sleep outcomes in patients with Parkinson’s disease: A post-hoc analysis of NMS-Nab study. Movement Disorders Clinical Practice, 9(6), 751-758. https://doi.org/10.1002/mdc3.13471
Peball, M., Krismer, F., Knaus, H.-G., Djamshidian, A., Werkmann, M., Carbone, F., Ellmerer, P., Heim, B., Marini, K., Valent, D., Goebel, G., Ulmer, H., Stockner, H., Wenning, G. K., Stolz, R., Krejcy, K., Poewe, W., Seppi, K., & Collaborators of the Parkinson’s Disease Working Group Innsbruck. (2020). Non- motor symptoms in Parkinson’s disease are reduced by nabilone. Annals of Neurology, 88(4), 712-722. https://doi.org/10.1002/ana.25864
Peres, F. F., Lima, A. C., Hallak, J. E. C., Crippa, J. A., Silva, R. H., & Abílio, V. C. (2018). Cannabidiol as a promising strategy to treat and prevent movement disorders? Frontiers in Pharmacology, 9, Article 482. https://doi.org/10.3389/fphar.2018.00482
Pérez-Olives, C., Rivas-Santisteban, R., Lillo, J., Navarro, G., & Franco, R. (2021). Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer’s, Parkinson’s, and Huntington’s Diseases. Advances in Experimental Medicine and Biology, 1264, 81-97. https://doi.org/10.1007/978-3-030-57369- 0_6
Pfeiffer, R. F. (2015). Non-motor symptoms in Parkinson's disease. Parkinsonism and Related Disorders. https://doi.org/10.1016/j.parkreldis.2015.09.004
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., Laezza, C., & Bifulco, M. (2017). Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology & Therapeutics, 175, 133-150. https://doi.org/10.1016/j.pharmthera.2017.02.041
Pizzolato, K., Thacker, D., Del Toro-Pagán, N., Hanna, A., Turgeon, J., Matos, A., Amin, N., & Michaud, V. (2021). Cannabis dopaminergic effects induce hallucinations in a patient with Parkinson’s disease. Medicina, 57(10), 1107. https://doi.org/10.3390/medicina57101107
Powell, A., Matar, E., & Lewis, S. J. G. (2020). Treating hallucinations in Parkinson’s disease. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2021.1851198
Qureshi, A. R., Rana, A. Q., Malik, S. H., Rizvi, S. F. H., Akhter, S., Vannabouathong, C., Sarfraz, Z., & Rana, R. (2018). Comprehensive Examination of Therapies for Pain in Parkinson’s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology, 51(3-4), 190-206. https://doi.org/10.1159/000492221
Rietcheck, H. R., Maghfour, J., Rundle, C. W., Husayn, S. S., Presley, C. L., Sillau, S. H., Liu, Y., Leehey, M. A., Dunnick, C. A., & Dellavalle, R. P. (2021). A review of the current evidence connecting seborrheic dermatitis and Parkinson’s disease and the potential role of oral cannabinoids. Dermatology, 237(6), 872-877. https://doi.org/10.1159/000512189
Russo, E. B. (2018). Cannabis Therapeutics and the Future of Neurology. Frontiers in Integrative Neuroscience, 12, 51. https://doi.org/10.3389/fnint.2018.00051
Santos, J. A., Oliveira, M. R., & Souza, L. P. (2024). Estudo sobre a aplicação de novas técnicas em neurologia. Research, Society and Development, 12(2), 45- 60. http://dx.doi.org/10.33448/rsd-v12i2.40345
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017). Non-motor features of Parkinson disease. Nature Reviews Neuroscience, 18(7), 435–450. https://doi.org/10.1038/nrn.2017.62
Shohet, A., Khlebtovsky, A., Roizen, N., Roditi, Y., & Djaldetti, R. (2017). Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson’s disease. European Journal of Pain, 21(3), 486-493. https://doi.org/10.1002/ejp.942
Silva, R. R. da, Silva, L. A. da, Santos, L. O. P. dos, Ribeiro, A. A., Sales, F. M., & Alencar, I. F. (2022). Uso terapêutico da cannabis medicinal em pessoas com doença neurológica degenerativa. Revista de Pesquisa Cuidado é Fundamental Online, 14, e11492. https://doi.org/10.9789/2175-5361.rpcfo.v14.11492
Scott, E. P., Brennan, E., & Benitez, A. (2019). A systematic review of the neurocognitive effects of cannabis use in older adults. Current Addiction Reports, 6(4), 443-455. https://doi.org/10.1007/s40429-019-00285-9
Stampanoni Bassi, M., Sancesario, A., Morace, R., Centonze, D., & Iezzi, E. (2017). Cannabinoids in Parkinson’s Disease. Cannabis and Cannabinoid Research, 2(1), 21-29. https://doi.org/10.1089/can.2017.0002
Stasiłowicz, A., Tomala, A., Podolak, I., & Cielecka-Piontek, J. (2021). Cannabis sativa L. as a natural drug meeting the criteria of a multitarget approach to treatment. International Journal of Molecular Sciences, 22(2), 778. https://doi.org/10.3390/ijms22020778
Suryadevara, U., Bruijnzeel, D. M., Nuthi, M., Jagnarine, D. A., Tandon, R., & Bruijnzeel, A. W. (2017). Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders. Current Neuropharmacology, 15(6), 800-814. https://doi.org/10.2174/1570159X14666161101095325
Tambe, S. M., Mali, S., Amin, P. D., & Oliveira, M. (2023). Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications. Journal of Integrative Medicine, 21(3), 236–244. https://doi.org/10.1016/j.joim.2023.03.004
Udow, S. J., Freitas, M. E., Fox, S. H., & Lang, A. E. (2018). Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. CMAJ, 190(2), E50-E52. https://doi.org/10.1503/cmaj.170361
Urbi, B., Corbett, J., Hughes, I., Owusu, M. A., Thorning, S., Broadley, S., Sabet, A., & Heshmat, S. (2021). Effects of Cannabis in Parkinson’s Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson’s Disease. https://doi.org/10.3233/JPD-212923
Velayudhan, L., McGoohan, K., & Bhattacharyya, S. (2021). Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. PLOS Medicine, 18(3), e1003524. https://doi.org/10.1371/journal.pmed.1003524
Velayudhan, L., Van Diepen, E., Marudkar, M., Hands, O., Suribhatla, S., Prettyman, R., Murray, J., Baillon, S., & Bhattacharyya, S. (2014). Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review. Current Pharmaceutical Design, 20(13), 00-00. https://doi.org/10.2174/13816128113199990434
Verma, R., Hoda, F., Arshad, M., Iqubal, A., Siddiqui, A. N., Khan, M. A., Haque, S. E., Akhtar, M., & Najmi, A. K. (2021). Cannabis, a miracle drug with polyvalent therapeutic utility: Preclinical and clinical-based evidence. Medical Cannabis and Cannabinoids, 4(1), 43-60. https://doi.org/10.1159/000515042
Viana, M. de B., de Aquino, P. E. A., Estadella, D., Ribeiro, D. A., & Viana, G. S. de B. (2022). Cannabis sativa and cannabidiol: A therapeutic strategy for the treatment of neurodegenerative diseases? Med Cannabis Cannabinoids, 5(1), 207–219. https://doi.org/10.1159/000527335
Wakabayashi, K., Tanji, K., Mori, F., & Takahashi, H. (2007). The Lewy body in Parkinson’s disease: Molecules implicated in the formation and degradation of α‐synuclein aggregates. Neuropathology, 27(5), 494–506. https://doi.org/10.1111/j.1440-1789.2007.00803.x
White, C. M. (2019). A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. The Journal of Clinical Pharmacology, 00(0), 1-12. https://doi.org/10.1002/jcph.1387
World Health Organization. (2022). Parkinson disease: a public health approach. Technical brief. Geneva: World Health Organization. Licence: CC BY-NC- SA 3.0 IGO.
Yan, J., Liu, A., Huang, J., Wu, J., Shen, R., Ma, H., & Yang, J. (2021). Pharmacological interventions for REM sleep behavior disorder in Parkinson’s disease: A systematic review. Frontiers in Aging Neuroscience, 13, 709878. https://doi.org/10.3389/fnagi.2021.709878
Yenilmez, F., Fründt, O., Hidding, U., & Buhmann, C. (2021). Cannabis in Parkinson’s Disease: The Patients’ View. Journal of Parkinson’s Disease, 11(2), 309-321. https://doi.org/10.3233/JPD-202260
Zuardi, A. W. (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista Brasileira de Psiquiatria, 30(3), 271-280. https://doi.org/10.1590/S1516-44462008000300015
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Pinto, J. P., Chagas, M. H. N., Rodrigues, G. G. R., Dursun, S. M., & Tumas, V. (2009). Cannabidiol for the treatment of psychosis in Parkinson's disease. Journal of Psychopharmacology, 23(8), 979-983. https://doi.org/10.1177/0269881108096519
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Gabriela Campos Piloto; Juliana Cristina da Silva; Kethlin Camargo Germann; Alexandra Czepula
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
